Probi AB, a leading probiotic research and development company from Sweden, and DKSH, the leading market expansion services provider with a focus on Asia, signed an agreement for the launch of Probi Digestis in Hong Kong and Macau.
Probi and DKSH have signed a long-term agreement for the branding and launch of Probi’s gastrointestinal health product Probi Digestis, based on Lactobacillus plantarum 299v, Probi’s clinically documented probiotic strain. The agreement is an expansion of the agreement signed in 2013 between Probi and BiO-LiFE, a Malaysian subsidary of DKSH.
The product will be marketed in a cobranded solution with BiO-LiFE and Probi Digestis and will be positioned against abdominal pain, bloating, constipation and flatulence. DKSH will market, sell and distribute the product in both medical channels such as clinics and hospitals as well as in pharmacies in Hong Kong and Macau.
“DKSH is an excellent partner in the growing Asian market and we are happy to step-by-step expand the collaboration we initiated with DKSH in 2013 around Probi´s clinically proven probiotic products,” says Peter Nählstedt, CEO of Probi.
"Following the launch of the probiotic product in Malaysia in 2013, we have been enjoying a very strong relationship with Probi AB. With the growth potential in dietary supplements for both Hong Kong and Macau, we are confident to successfully launch Probi Digestis in these two markets," said Richard Holloway, vice president of Business Unit Healthcare, DKSH Hong Kong.
To further strengthen its presence in Asia Pacific, Probi has expanded its marketing and sales organization with a regional director based in Singapore. “By having a Probi employee working on a day-to-day basis in Asia we will be able to give our partners strong support and intensify business developement activities. This is the first step in the expansion and globalization of Probi´s Marketing and Sales team,” says Peter Nählstedt, CEO of Probi.